New drug trial targets uncontrollable hunger in rare genetic disorder
Symptom relief
Not yet recruiting
This study is testing whether a new oral medication called BMB-101 can safely reduce the severe, constant hunger experienced by adults with Prader-Willi Syndrome (PWS). Sixteen participants will be randomly assigned to receive either the real drug or a placebo for 16 weeks, follo…
Phase: PHASE2 • Sponsor: Bright Minds Biosciences Pty Ltd • Aim: Symptom relief
Last updated Mar 18, 2026 14:41 UTC